Anti-Human MC4R Therapeutic Antibody (1E8a)

Figure 1 Immunocytochemistry of HEK-293 cells transfected with hMC4R or hMC3R.

The specific membrane labeling was seen in HEK-293 cells expressing hMC4R when incubated with the mAb 1E8a.

Peter, J. C., Lecourt, A. C., Weckering, M., Zipfel, G., Niehoff, M. L., Banks, W. A., & Hofbauer, K. G. (2010). A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration. Journal of pharmacology and experimental therapeutics, 333(2), 478-490.

Figure 2 The inhibition of hMC4R immunoprecipitation by mAb 1E8a using increasing concentration of the NT peptide.

Results are presented as percentage of inhibition of the
signal obtained without NT peptide in function of the [NT].
Mean=S.D. are calculated from three independent experiments.
n=5 measurements/experiment.

Peter, J. C., Lecourt, A. C., Weckering, M., Zipfel, G., Niehoff, M. L., Banks, W. A., & Hofbauer, K. G. (2010). A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration. Journal of pharmacology and experimental therapeutics, 333(2), 478-490.

Figure 3 Western blot probed with an anti-His6 Ab that revealed the presence of the His6-tagged scFv 1E8a.

Purification of the scFv 1E8a by Ni-NTA chromatography.

Peter, J. C., Lecourt, A. C., Weckering, M., Zipfel, G., Niehoff, M. L., Banks, W. A., & Hofbauer, K. G. (2010). A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration. Journal of pharmacology and experimental therapeutics, 333(2), 478-490.